News & events

the Annual General Meeting of Clavis Pharma ASA was held on 17 June 2013. Please find the minutes of the Annual General Meeting attached

Reference is made to the announcement of 24 May 2013 regarding Clavis Pharma ASA's Annual General Meeting 2013, and agenda item 6 and 8: Remuneration for the Board of Directors and Election of Board members.

Please follow the link below to VPS for electronical registration to attend the Extraordinary General Meeting on 17 June 2013 at 14:00 hours at Parkveien 53B, Oslo. The link will be activated on Monday 27 May.

Martin Nes, a board member of the Company, as Interim Chairman of the Board of Directors and Gunnar Manum, the CFO of Clavis Pharma, to the additional position of Acting CEO

announces that the Chairman, Anders P. Wiklund, and the board members Annette Clancy and Hilde H. Steineger, have decided to resign from the Board of Directors of Clavis Pharma ASA.

Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug development company, announces that Olav Hellebø will leave the position as CEO of the company effective 20 May by mutual agreement.

The Extraordinary General Meeting elected Martin Nes and Øystein Stray Spetalen as new directors.

Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug development company, announces its results for the first quarter 2013, and including significant post-period events.

Proposal for the extraordinary shareholders meeting May 2^nd 2013

Please follow the link below to VPS for electronical registration to attend the Extraordinary General Meeting on 2 May 2013 at 13:00 hours at Parkveien 53B, Oslo.